Search Results

You are looking at 61 - 70 of 109 items for :

  • "aromatase inhibitor" x
  • All content x
Clear All
Full access

D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff

2006 ; 11 : 704 – 717 . 42 Miller WR Bartlett J Brodie AM . Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008 ; 13 : 829 – 837 . 43 Normanno

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy, and Cynthia X. Ma

significantly improve PFS compared with hormone therapy alone in patients with advanced HR+/HER2– breast cancer, 6 , 7 leading to FDA approval of palbociclib in combination with an aromatase inhibitor (AI; as first-line therapy) in February 2015, and with

Full access

Arvind Bambhroliya, Mariana Chavez-MacGregor, and Abenaa M. Brewster

proven to be 76% as effective as tamoxifen in reducing the overall risk of invasive breast cancer (RR, 1.24; 95% CI, 1.05–1.47). 6 Two aromatase inhibitors have been investigated for the primary prevention of breast cancer. MAP.3 was a randomized

Full access

Rondi M. Kauffmann, Leanne Goldstein, Emily Marcinkowski, George Somlo, Yuan Yuan, Philip H.G. Ituarte, Laura Kruper, Leslie Taylor, and Courtney Vito

/radiation, or mastectomy. 1 When breast conservation is used, the risk of local recurrence is higher than with mastectomy. 1 Antiestrogen (anti-e) therapy, in the form of either tamoxifen or an aromatase inhibitor (AI), may be used to reduce the risk of local

Full access

Adam L. Cohen and John H. Ward

with breast cancer stop taking it early. 15 – 17 Therefore, an individualized approach to balancing the benefits and risks of tamoxifen is appropriate. Risk Reduction With Other Drugs Both aromatase inhibitors and human epidermal growth factor

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

postmenopausal women, except that tamoxifen is the preferred adjuvant treatment. 5 – 9 There are limited clinical data on the efficacy of single-agent aromatase inhibitors in men, and aromatase inhibitors may be combined with gonadotropic hormone

Full access

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, and Matthew R. Smith

-up of the effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole . Presented at the 2006 San Antonio Breast Cancer Symposium ; December 14–17, 2006 ; San

Full access

Rachel F. Dear, Kevin McGeechan, Megan B. Barnet, Alexandra L. Barratt, and Martin H.N. Tattersall

premenopausal women with early-stage breast cancer; the NCCN Guidelines recommend tamoxifen alone. The AGO guidelines recommend either tamoxifen or an aromatase inhibitor (AI) for postmenopausal women with early-stage breast cancer; the NCCN Guidelines

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

will receive endocrine therapy (tamoxifen or an aromatase inhibitor [AI]; category 1). Adjuvant RT After Mastectomy Multiple trials have reported decrease in locoregional recurrence and OS benefit in patients receiving postmastectomy RT (PMRT

Full access

Namratha Vontela, Vamsi Koduri, Lee S. Schwartzberg, and Gregory A. Vidal

testosterone and its derivatives with some clinical efficacy. 2 However, androgen therapy fell out of favor due to concerns of aromatization to its virilizing effects, and the availability of tamoxifen and third-generation aromatase inhibitors (AIs). 3